Reminyl® (galantamine hydrobromide): New warning on serious skin reactions (Stevens Johnson syndrome and acute generalised exanthematous pustulosis)

Janssen, a division of Johnson & Johnson Pte Ltd, would like to alert healthcare professionals to the risk of serious skin reactions that have been reported with the use of Reminyl® (galantamine hydrobromide). Stevens Johnson syndrome (SJS) and acute generalised exanthematous pustulosis (AGEP) have been reported in patients receiving Reminyl®. Patients should be informed about the signs of serious skin reactions, and that use of Reminyl® should be discontinued at the first appearance of skin rash. These warnings regarding serious skin reactions are in the process of being updated in the Reminyl® Singapore package insert, with SJS and AGEP to be included as new adverse reactions. Please refer to the letter for more information.

 
 
Healthcare professional, Therapeutic Products
Published:

Dear Healthcare Professional Letters

12 Dec 2019

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of the letters can be found on the MOH Alert System, which is accessible via the Health Professionals Portal (HPP). HPP is a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://www.moh.gov.sg/hpp/, and follow the procedures below to access the MOH Alert system.

Step 1: On the top navigation ribbon of webpage, select 'For Healthcare Professionals' followed by 'Health Professionals Portal' and click on the choice of profession. User will be redirected to the specific HPP webpage for the selected profession.

Step 2: Click on the Restricted Content icon on the left panel of webpage and login via SingPass.

Step 3: Click on the MOH Alert icon under ‘Applications’ section

Step 4: Click on the Drug Alert tab to view the DHCPLs.